Eli Lilly and Company today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion.
The investment will incorporate new process designs and technologies at Lilly Lebanon API, one of the company's future active pharmaceutical ingredient sites, as well as Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility opening today.
Lilly Lebanon Advanced Therapies is designed to support both clinical and commercial production of advanced therapies that target disease at the genetic level and will include a full spectrum of genetic medicine modalities from research-stage development through large-scale commercial supply. Designing and building for these modalities required developing new manufacturing processes without established commercial precedent. This facility is the first of three planned sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.
Lebanon, Indiana, is the cornerstone of Lilly's domestic manufacturing buildout. In 2024, Lilly announced plans to make both Zepbound (tirzepatide) and Mounjaro (tirzepatide), the most prescribed injectable medications for weight management and type 2 diabetes respectively, at its Lebanon API site. Today's investment expands that commitment further, including planned production of Foundayo (orforglipron), Lilly's first FDA-approved, once-daily pill for weight loss that can be taken without food or water restrictions,3 and retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease.
"Lilly's legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next," said David A. Ricks, Lilly chair and CEO. "From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world's most advanced plants to make them. When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home."
Lilly's U.S. capital expansion commitments since 2020 total more than $50 billion, investments made possible thanks to policies that promote domestic manufacturing. The company plans to break ground on several of its recently announced U.S. manufacturing sites this year.
